Iaso Therapeutics, Inc. is an early-stage start-up spun out from Michigan State University structured around development of next generation vaccines to enhance human health and treat diseases. A priority of the firm is to translate the cutting-edge technologies developed in the laboratory of one of the Founders to promote human health and treat diseases. In that vein,the company has developed a proprietary mutant bacteriophage Q? (mQ?) platform technology. Head-to-head comparison studies of mQ? against those using the benchmark carriers suggest that Iaso's mQ? conjugates can elicit more powerful immune responses. This exciting technology is being applied to vaccines against a variety of diseases including cancer and infectious diseases. Vaccines have protected humankind from many deadly infections including smallpox, yellow fever, and tetanus, saving millions of lives. However, the rampage of the COVID-19 over the world serves as a painful reminder of the lack of effective vaccines against many other diseases. Novel technologies that can be readily deployed for new vaccines, especially against newly emerged pathogens, are urgently needed. Iaso Therapeutics is dedicated to developing next generation vaccines to enhance human health and treat diseases.
